Johnson & Johnson's first quarter orthopedics sales were flat, with sales in the United States dropping 3.5 percent. The company reported $1.4 million in worldwide orthopedics sales, which was slightly below the $1.5 million reported in the first quarter of 2011. The company's international orthopedics sales increased 2.6 percent, which offset a decrease in the U.S. market.
During the first quarter, the company reported $271 million in expenses related to litigation and the DePuy ASC Hip recall costs.
More Articles on Orthopedic Devices:
Johnson & Johnson's Synthes Acquisition Finally Approved
NLT Spine Receives CE Mark for Discectomy Device
Stryker Q1 Sales Soar 7.2%, Spine Sales Driven by Acquisitions
During the first quarter, the company reported $271 million in expenses related to litigation and the DePuy ASC Hip recall costs.
More Articles on Orthopedic Devices:
Johnson & Johnson's Synthes Acquisition Finally Approved
NLT Spine Receives CE Mark for Discectomy Device
Stryker Q1 Sales Soar 7.2%, Spine Sales Driven by Acquisitions